Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) have been assigned an average recommendation of “Moderate Buy” from the six ratings firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $8.00.

MIST has been the subject of several research analyst reports. TD Cowen raised shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, December 15th. HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of Milestone Pharmaceuticals in a report on Tuesday, January 6th. Zacks Research raised Milestone Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 26th. Wells Fargo & Company boosted their price target on Milestone Pharmaceuticals from $4.00 to $8.00 and gave the company an “overweight” rating in a research report on Tuesday, December 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research note on Monday, December 29th.

Insider Buying and Selling at Milestone Pharmaceuticals

In other news, insider David Bharucha sold 58,007 shares of the firm’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $2.32, for a total value of $134,576.24. Following the transaction, the insider owned 91,993 shares of the company’s stock, valued at approximately $213,423.76. This trade represents a 38.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Jeffrey Edward Nelson sold 58,007 shares of Milestone Pharmaceuticals stock in a transaction on Monday, December 15th. The shares were sold at an average price of $2.32, for a total transaction of $134,576.24. Following the transaction, the chief operating officer owned 41,993 shares in the company, valued at $97,423.76. The trade was a 58.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 416,327 shares of company stock worth $935,458 in the last quarter. Company insiders own 19.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Propel Bio Management LLC lifted its stake in shares of Milestone Pharmaceuticals by 186.1% during the third quarter. Propel Bio Management LLC now owns 5,124,890 shares of the company’s stock worth $10,250,000 after purchasing an additional 3,333,333 shares in the last quarter. Orbimed Advisors LLC purchased a new stake in shares of Milestone Pharmaceuticals during the 3rd quarter valued at about $6,444,000. Simplify Asset Management Inc. lifted its position in Milestone Pharmaceuticals by 186.2% during the 3rd quarter. Simplify Asset Management Inc. now owns 2,832,974 shares of the company’s stock worth $5,666,000 after acquiring an additional 1,842,974 shares in the last quarter. Marshall Wace LLP boosted its holdings in Milestone Pharmaceuticals by 289.8% in the 4th quarter. Marshall Wace LLP now owns 1,656,821 shares of the company’s stock worth $3,347,000 after acquiring an additional 1,231,793 shares during the period. Finally, Pathstone Holdings LLC acquired a new stake in Milestone Pharmaceuticals in the third quarter valued at approximately $2,000,000. 86.18% of the stock is owned by hedge funds and other institutional investors.

Milestone Pharmaceuticals Price Performance

MIST stock opened at $1.70 on Friday. The stock has a market capitalization of $144.79 million, a price-to-earnings ratio of -2.07 and a beta of 0.46. The company has a quick ratio of 8.24, a current ratio of 8.24 and a debt-to-equity ratio of 2.74. Milestone Pharmaceuticals has a 52-week low of $0.63 and a 52-week high of $3.06. The stock’s fifty day simple moving average is $2.06 and its 200-day simple moving average is $1.99.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its earnings results on Wednesday, November 12th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.05. Equities research analysts expect that Milestone Pharmaceuticals will post -0.62 EPS for the current year.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.